United States-based global pharmaceutical company MSD said on Monday that China's National Medical Products Administration has approved the use of multiple new indications of Gardasil®9, its ...

MRK posts better-than-expected first-quarter results but trims its 2025 EPS outlook due to anticipated one-time charges.

Selling, general and administrative expenses were $2.6 billion in the first quarter, Merck noted, an increase of 3% compared with the first quarter of 2024. The increase was primarily due to higher ...

MSD's Gardasil 9, which is India's first gender-neutral HPV vaccine, is also available. The 9-valent HPV vaccine targets sub-types 6, 11, 16, 18, 31, 33, 45, 52 and 58 among Indian girls and women ...

In vaccines, sales of HPV vaccines — Gardasil and Gardasil 9 — fell 40% to $1.33 billion ... Sales of the pneumococcal 15-valent conjugate vaccine Vaxneuvance rose 7% to $230 million ...

MSD's Gardasil 9, which is India's first gender-neutral HPV vaccine, is also available. The 9-valent HPV vaccine targets sub-types 6, 11, 16, 18, 31, 33, 45, 52 and 58 among Indian girls and women ...

MSD's Gardasil 9, which is India's first gender-neutral HPV vaccine, is also available. The 9-valent HPV vaccine targets sub-types 6, 11, 16, 18, 31, 33, 45, 52 and 58 among Indian girls and women ...